RSCM
Rock Springs Capital Management’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.5M | Hold |
812,653
| – | – | 1.03% | 32 |
|
|
2025
Q1 | $14.7M | Sell |
812,653
-409,529
| -34% | -$7.43M | 0.84% | 44 |
|
|
2024
Q4 | $30.9M | Buy |
1,222,182
+118,404
| +11% | +$2.99M | 1.18% | 31 |
|
|
2024
Q3 | $37.5M | Sell |
1,103,778
-295,216
| -21% | -$10M | 1.22% | 33 |
|
|
2024
Q2 | $51.8M | Buy |
1,398,994
+26,809
| +2% | +$992K | 1.56% | 22 |
|
|
2024
Q1 | $57.6M | Buy |
1,372,185
+402,539
| +42% | +$16.9M | 1.46% | 22 |
|
|
2023
Q4 | $38.5M | Buy |
969,646
+469,545
| +94% | +$18.6M | 0.95% | 37 |
|
|
2023
Q3 | $13.8M | Buy |
500,101
+78,486
| +19% | +$2.16M | 0.37% | 65 |
|
|
2023
Q2 | $14.3M | Buy |
421,615
+111
| +0% | +$3.77K | 0.34% | 68 |
|
|
2023
Q1 | $15.2M | Hold |
421,504
| – | – | 0.36% | 68 |
|
|
2022
Q4 | $18.8M | Sell |
421,504
-100
| -0% | -$4.46K | 0.45% | 60 |
|
|
2022
Q3 | $11.9M | Buy |
421,604
+86,127
| +26% | +$2.42M | 0.31% | 72 |
|
|
2022
Q2 | $9.04M | Buy |
335,477
+238,160
| +245% | +$6.42M | 0.26% | 81 |
|
|
2022
Q1 | $3.32M | Buy |
+97,317
| New | +$3.32M | 0.08% | 116 |
|